Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Regenerative Medicine International Limited
中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8158)

VOLUNTARY ANNOUNCEMENT FORMAL TERMINATION OF THE DISCLOSEABLE TRANSACTION IN RELATION TO THE SUBSCRIPTION OF INCREASED REGISTERED CAPITAL IN THE TARGET COMPANY

Reference is made to the announcements of China Regenerative Medicine International Limited (the "**Company**") dated 29 December 2023, 15 January 2024 and 2 February 2024 (collectively, the "**Announcements**") in relation to Capital Contribution in the Target Company by CRMI Health. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated herein.

The Board wishes to inform the Shareholders that, as the change of Company's business strategy and management, and certain conditions precedent set out in the Capital Increase and Subscription Agreement have not been fulfilled or waived by the agreed date, on 31 October 2025, the Parties to the Capital Increase and Subscription Agreement agreed to enter into a formal termination agreement (the "**Termination Agreement**"), pursuant to which the Parties have agreed to terminate the Capital Increase and Subscription Agreement with immediate effect in accordance with the terms of the Termination Agreement, and no party to the Capital Increase and Subscription Agreement shall have any claim against any other party, except in respect of rights and liabilities accrued prior to the termination.

As disclosed in the announcement dated 29 December 2023, if any of the conditions precedent is not satisfied or waived before the Long Stop Date unless all Parties agree in writing to extend the time for fulfillment of the conditions precedent, the Capital Increase and Subscription Agreement shall automatically be terminated. As such, the entering into of the Termination Agreement is merely procedural and for proper record purpose by all Parties, and there is no material change or effect in the arrangement previously agreed by the Parties in the Capital Increase and Subscription Agreement.

The Board is of the view that the termination of the Capital Increase and Subscription Agreement will not have any material adverse impact on the business, operation and the financial position of the Group and the interests of the Shareholders as a whole.

By Order of the Board
China Regenerative Medicine International Limited
Wang Chuang
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 31 October 2025

As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Ms. Luo Min, and the independent non-executive Directors are Ms. Huo Chunyu, Mr. Zhou Xudong and Mr. Leung Man Fai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkexnews.hk for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.